CARILEX Stocks

NT$ 38.3Last Updated 09.03.2026

Issuer Rating

3/7

Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 24.43M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 38.3
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Carilex Medical, Inc. engages in the manufacturing of medical devices to prevent pressure ulcers and wound care management. Its products include medical grade air beds, chair cushion and negative pressure wound treatment machine. The company was founded on May 23, 2012 and is headquartered in Taoyuan, China.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA, trading at neutral

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks